Short Interest in Biofrontera Inc. (NASDAQ:BFRI) Grows By 675.7%

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totaling 255,272 shares, a growth of 675.7% from the August 15th total of 32,907 shares. Based on an average daily trading volume, of 674,900 shares, the short-interest ratio is presently 0.4 days. Approximately 1.9% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on BFRI shares. Zacks Research raised shares of Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Wall Street Zen raised shares of Biofrontera to a “hold” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Biofrontera has a consensus rating of “Hold”.

Institutional Investors Weigh In On Biofrontera

An institutional investor recently raised its position in Biofrontera stock. Rosalind Advisors Inc. boosted its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 51.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera comprises about 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th biggest position. Rosalind Advisors Inc. owned 9.63% of Biofrontera worth $695,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 10.08% of the company’s stock.

Biofrontera Price Performance

Biofrontera stock opened at $1.46 on Friday. The business has a 50 day simple moving average of $1.29 and a 200 day simple moving average of $1.07. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. The company has a market capitalization of $21.68 million, a PE ratio of -3.24 and a beta of 0.83. Biofrontera has a one year low of $0.55 and a one year high of $1.66.

Biofrontera (NASDAQ:BFRI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.05. Biofrontera had a negative return on equity of 145.81% and a negative net margin of 13.78%.The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $9.50 million. On average, sell-side analysts forecast that Biofrontera will post -0.6 EPS for the current fiscal year.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.